Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: Final results of a phase II trial

Oncology

Volumn 82, Issue 2, 2012, Pages 67-74

  Kaseb, A O ^a   Garrett Mayer, E ^b   Morris, J S ^a   Xiao, L ^a   Lin, E ^a   Onicescu, G ^b   Hassan, M M ^a   Hassabo, H M ^a   Iwasaki, M ^a   Deaton, F L ^a   Abbruzzese, J L ^a   Thomas, M B ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Bevacizumab; Biomarkers; Erlotinib; Hepatocellular carcinoma; Targeted therapy

Indexed keywords

ALPHA FETOPROTEIN; AMINOTRANSFERASE; ANGIOPOIETIN 2; BEVACIZUMAB; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLATELET DERIVED GROWTH FACTOR BB; SORAFENIB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEAD PAIN; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERPIGMENTATION; HYPERTENSION; LIVER CELL CARCINOMA; LOWER GASTROINTESTINAL HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; SIDE EFFECT; TASTE; TASTE ALTERATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER GASTROINTESTINAL BLEEDING; VOICE CHANGE; VOMITING; WOUND INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84863407817     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000335963     Document Type: Article

References (30)

1. Mortality database. WHO statistical information system. http://www.who.int/whosis, 2007.
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
3. Lang L: FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 2008; 134: 379. (Pubitemid 351173079)
4. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL: Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17: 1973-1983.
5. Bekaii-Saab T, Markowitz J, Prescott N, Sadee W, Heerema N, Wei L, Dai Z, Papp A, Campbell A, Culler K, Balint C, O'Neil B, Lee RM, Zalupski M, Dancey J, Chen H, Grever M, Eng C, Villalona-Calero M: A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009; 15: 5895-5901.
6. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RS Jr, Rafii S, Schwartz JD: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26: 2992-2998.
7. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035.
8. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M, Ono M: ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002; 62: 2554-2560. (Pubitemid 34462734)
9. Tamesa T, Iizuka N, Mori N, Okada T, Takemoto N, Tangoku A, Oka M: High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1122-1126.
10. Giannelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A: EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Lett 2008; 262: 257-264.
11. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-1067. (Pubitemid 47312872)
12. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005; 23: 6657-6663. (Pubitemid 46190260)
13. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J: Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009; 27: 843-850.
14. Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
15. Thall PF, Simon RM, Estey EH: Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995; 14: 357-379.
16. Matsumoto H, Uemasu J, Kitano M, Kawasaki H: Clinical significance of plasma endothelin-in patients with chronic liver disease. Dig Dis Sci 1994; 39: 2665-2670.
17. Chen CY, Lu CL, Chang FY, Lih-Jiun K, Luo JC, Lu RH, Lee SD: Delayed gastrointestinal transit in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2002; 17: 1254-1259. (Pubitemid 35363303)
18. Notas G, Xidakis C, Valatas V, Kouroumalis A, Kouroumalis E: Levels of circulating endothelin-and nitrates/nitrites in patients with virus-related hepatocellular carcinoma. J Viral Hepat 2001; 8: 63-69. (Pubitemid 32115915)
19. Nakamuta M, Ohashi M, Tabata S, Tanabe Y, Goto K, Naruse M, Naruse K, Hiroshige K, Nawata H: High plasma concentrations of endothelin-like immunoreactivities in patients with hepatocellular carcinoma. Am J Gastroenterol 1993; 88: 248-252. (Pubitemid 23053479)
20. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277: 55-60. (Pubitemid 27450643)
21. Yu Q, Stamenkovic I: Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. Am J Pathol 2001; 158: 563-570. (Pubitemid 32158617)
22. Scholz A, Rehm VA, Rieke S, Derkow K, Schulz P, Neumann K, Koch I, Pascu M, Wiedenmann B, Berg T, Schott E: Angiopoietin-serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. Am J Gastroenterol 2007; 102: 2471-2481. (Pubitemid 47631757)
23. Torimura T, Ueno T, Kin M, Harada R, Taniguchi E, Nakamura T, Sakata R, Hashimoto O, Sakamoto M, Kumashiro R, Sata M, Nakashima O, Yano H, Kojiro M: Overexpression of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. J Hepatol 2004; 40: 799-807. (Pubitemid 38507361)
24. Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC, Yeum JH, Koh GY, Tarnawski AS: Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol 2003 16 552-557. (Pubitemid 36718436)
25. Llovet J, Peña C, Shan M, Lathia C, Bruix J: Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma: results from the randomized phase III SHARP trial. Copenhagen, EASL Annual Meeting, 2009.
26. Reig ME, Rodriguez de Lope C, Forner A, Rimola J, Lopez-Oliva JM, Tremosini S, Ayuso C, Llovet JM, Boix S, Bruix J: Impact of early treatment interruption and biomarker profiling in patients with HCC treated with sorafenib (abstract 1748). Boston, Annual Meeting of the American Association for Study of Liver Diseases, 2010.
27. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Uemura M, Masaki T, Fukui H: Angiopoietin displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut 2005; 54: 1768-1775. (Pubitemid 41697677)
28. Lobov IB, Brooks PC, Lang RA: Angiopoietin-displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA 2002; 99: 11205-11210. (Pubitemid 34920903)
29. Coxon A, Rex K, Sun JR, et al: Combined treatment of angiopoietin and VEGF pathway antagonists enhances antitumor activity in preclinical models of colon carcinoma (abstract 1113). San Diego, 99th Annual Meeting of the American Association for Cancer Research, 2008.
30. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Instit 2008; 100: 698-711.